Wednesday, June 10, 2026

Patent intelligence Β· EP

EP 3182958

ARIPIPRAZOL-PRODRUGZUSAMMENSETZUNG

granted A61K 9/ 00 A IA61K 9/ 14 A IA61K 31/ 4704 A IA61K/3100
Status granted
Pipeline programs 6
Years to expiry 11
Applicant portfolio 25
Patent details β€” EP 3182958
Jurisdiction
EP
Status
granted
Grant date
Jun 28, 2017
Expiration
Jun 23, 2037
CPC classes
A61K 9/ 00 A I, A61K 9/ 14 A I, A61K 31/ 4704 A I, A61K/3100
View on Google Patents β†—

Quick answer

EP 3182958 (ARIPIPRAZOL-PRODRUGZUSAMMENSETZUNG) is held by ALKERMES PHARMA IRELAND LTD [IE]. Status: granted. Granted Jun 28, 2017. Expires Jun 23, 2037 (11 years remaining) β€” relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
β€”
CPC classes
A61K 9/ 00 A I, A61K 9/ 14 A I, A61K 31/ 4704 A I, A61K/3100, A61K/31496, A61K/4506

More from ALKERMES PHARMA IRELAND LTD [IE]

Related pharmaceutical patents in our USPTO index.

  1. AU 2022263543

    Pharmaceutical compositions comprising sorbitan esters

    ALKERMES PHARMA IRELAND LTD [IE] Β· Expires May 18, 2044

    granted
  2. US 2023302008

    METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE

    ALKERMES PHARMA IRELAND LTD [IE] Β· Expires Sep 23, 2043

    granted
  3. WO 2023156493

    FORMES CRISTALLINES DE NALTREXONE

    ALKERMES PHARMA IRELAND LTD [IE] Β· Expires Aug 19, 2043

    granted
  4. WO 2023154894

    COMPOSITIONS ET PROCÉDÉS D'IMMUNOTHÉRAPIE ANTICANCÉREUSE

    ALKERMES PHARMA IRELAND LTD [IE] Β· Expires Aug 12, 2043

    granted
  5. CY 2022006

    Ξ Ξ‘ΞŸΞ¦Ξ‘Ξ‘ΞœΞ‘ΞšΞ‘ ΦΟΞ₯ΞœΞ‘Ξ‘Ξ™ΞšΞ©Ξ ΑΛΑ΀ΩΝ ΞšΞ‘Ξ™ Ξ— ΧΑΗΣΗ ΀ΟΞ₯Ξ£ Σ΀ΗΝ ΑΓΩΓΗ Ξ ΞŸΞ™ΞšΞ™Ξ›Ξ©Ξ ΝΟΣΩΝ

    ALKERMES PHARMA IRELAND LTD [IE] Β· Expires Dec 31, 2042

    granted
  6. US 2022354866

    IMMEDIATE RELEASE MULTILAYER TABLET

    ALKERMES PHARMA IRELAND LTD [IE] Β· Expires Nov 5, 2042

    granted
  7. CA 3172871

    COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION

    ALKERMES PHARMA IRELAND LTD [IE] Β· Expires Nov 13, 2041

    granted
  8. CA 3172874

    COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION

    ALKERMES PHARMA IRELAND LTD [IE] Β· Expires Nov 13, 2041

    granted

Frequently asked questions

What is US patent 3182958?

EP 3182958 (ARIPIPRAZOL-PRODRUGZUSAMMENSETZUNG) is held by ALKERMES PHARMA IRELAND LTD [IE]. Status: granted. Granted Jun 28, 2017. Expires Jun 23, 2037 (11 years remaining) β€” relevant for patent-cliff and LOE planning.

Who owns EP 3182958?

ALKERMES PHARMA IRELAND LTD [IE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does EP 3182958 expire?

Our index shows an expiration date of Jun 23, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.